QOP
UTHR icon

Quinn Opportunity Partners’s United Therapeutics UTHR Stock Holding History

Quinn Opportunity Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,403
Closed -$2.05M – 218
2022
Q1 		$2.05M Buy
+11,403
New +$2.17M 0.09% 94

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Quinn Opportunity Partners's UTHR Position: Q2 2022 in Review

Quinn Opportunity Partners sold out of United Therapeutics (UTHR) in Q2 2022, closing a stake of 11,403 shares — an estimated $2.05M sold.

Quinn Opportunity Partners first reported a position in UTHR in Q1 2022 and held it in 1 quarter. The position peaked at $2.05M in Q1 2022. 472 funds tracked by Wall St. Rank hold UTHR as of Q2 2022.

  • Quinn Opportunity Partners reported no remaining United Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Quinn Opportunity Partners sold 11,403 United Therapeutics shares in Q2 2022, an estimated $2.05M.
  • Quinn Opportunity Partners first reported a position in United Therapeutics in Q1 2022 and held it in 1 quarter.
  • Quinn Opportunity Partners's United Therapeutics position peaked at $2.05M in Q1 2022.
  • 472 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2022.

Based on Quinn Opportunity Partners's 13F filing for Q2 2022, filed 15 Aug 2022.